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Combined Evaluation of IGF-1 and IGFBP-3 as an Index




Guidelines about growth hormone (GH) dosing continue
to evolve and new data on the efficacy and safety of GH
treatment keep emerging. Recently, concerns have been
raised regarding excessive GH exposure in patients 
receiving GH therapy manifested as elevated insulin like
growth factor (IGF)-1 levels. Age-adjusted IGF-1 is 
generally accepted as the biochemical marker to monitor
GH treatment. It is known that serum (IGF)-1 values are
above the age-related reference range in several patients
receiving GH therapy. Whether GH dose should be altered
or therapy discontinued accordingly is a controversial issue
(1-3). IGF binding protein (IGFBP)-3 is also a GH dependent
parameter and is affected by GH dose in a similar way. 
IGF-1 makes up a complex with IGFBP-3 and acid labile 
subunit. The molar ratio of IGF-1 and IGFBP-3 reflects the
availability of the free form of IGF-1 which is effective for
growth stimulation. Using the molar ratio was suggested
as a safety index of GH treatment (4).  
The aim of this study was to evaluate IGF-1 and IGFBP-3
levels and molar ratio in patients on GH treatment and to
compare these parameters with the growth response of
the patients.
Methods
In this longitudinal study, 50 GH deficient children 
were evaluated during a 3-year period. The diagnosis of GH
deficiency was made on the basis of clinical and laboratory
data. Children with short stature (height below -3 SDS for
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25th centile for age), delayed bone age (more than 2 years)
and subnormal GH secretion (GH max <10 ng/ml) in two
provocative tests (L-Dopa and insulin tolerance tests) 
were diagnosed as GH deficient. Within the GH deficient
group, 35 patients were diagnosed as isolated complete
GH deficiency (peak GH response to stimulation tests  
<5 ng/ml) and 15 patients had isolated partial GH 
deficiency (peak GH response to stimulation tests
>5ng/ml to <10 ng/ml). Patients with multiple growth 
hormone deficiency were not included in the study. 
Recombinant human GH therapy was given to patients in
a dose of 0.2 mg/kg/week. Growth response of GH 
treated patients was evaluated as delta height SDS (the
difference in height SDS between basal value and that 
found in the consecutive year). 
IGF-1 was determined in the serum by an immunora-
diometric assay [IRMA, Diagnostic Systems Laboratories 
(DSL-5600), Webster, Tex., USA]. IGFBP-3 was measured
by IRMA using DSL-6600. IGF-1 and IGFBP-3 were 
expressed as SDS (5).  
For calculating the “molar ratio” of IGF-1 to IGFBP-3,
the following molecular masses were used: IGF-1  7.5 kD
and IGFBP-3 42kD (6).
The statistical analyses were done using the SPSS 
package programme. Kruskal Wallis, Pearson’s correlation
and Mann-Whitney U tests were used. 
Results
All patients completed the first year of therapy, 38 
patients the second year and 26 patients the third year of
therapy. Yearly height gain, expressed as delta height
SDS, and parameters related to IGF-1 and IGFBP-3 are
shown on Table 1. Fifteen patients in the first year, 5 
patients in the second year and 5 patients in the third 
year were found to have high IGF-1 SDS values for age
and pubertal status.  
There was no correlation between IGF-1 SDS and 
delta height SDS over the first year (p=0.53). No extra 
height gain was observed in patients with IGF-1 SDS 
values higher than +2 SDS. Molar ratio was also not 
different in patients with high IGF-1 SDS as compared to
patients with normal or low IGF-1 SDS (Fig. 1). 
During three  years of treatment height gain was not
correlated to IGF-1 SDS.  (Correlation coefficients were:  
r=-0.082, and p=0.618 for the first year of treatment, 
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Table 1. Height increments expressed as  delta (   ) height SDS and  parameters related to IGF-1, IGFBP-3 and molar ratio in GH deficient children receiving GH treatment
H He ei ig gh ht t   S SD DS S H He ei ig gh ht t   S SD DS S I IG GF F- -1 1   ( (n ng g/ /m ml l) ) I IG GF F- -1 1   S SD DS S I IG GF FB BP P- -3 3   ( (n ng g/ /m ml l) ) I IG GF FB BP P- -3 3   S SD DS S M Mo ol la ar r   r ra at ti io o
At diagnosis  -3.31±1.25 - 143.3±131.7 -2.16±1.44 3226.2±1771.7 -2.3±2.25 0.0062±0.005
(n:50) -8,60 to -0.46 - (1-747) -5.5 to 0.43 (626-7210) -7.43 to 2.29 (0.0002-0.019)
1st year of  -2.64±1.1 0.62±0.69 369.9±282.2 -0.06±2.17 4558.5±1676.7 -0.99±2.15 0.016±0.009
treatment (n:50) -6.78 to 0.58 -0.49 to 2.09 (10-1336) -6.78 to 4.1 (1030-7610) -6.43 to 3.24 (0.0005-0.034)
2nd year of  -2.41±0.93 0.31±0.5 381.34±314.1 -0.38±2.65 4312.1±1693.14 -1.73±1.85 0.019±0.016
treatment (n:38) -5.06 to 0.64 -0.81 to 1.69 (30-1349) -5.48 to 5 (841-7460) -6.15 to 1.33 (0.0024-0.079)
3rd  year of  -2.27±0.87 0.34±0.51 467.1±316.09 -0.15±2.45 5075±1365 -0.77±1.65 0.019±0.014
treatment (n:26) -4.35 to -0.8 -0.64 to 1.75 (70-1288) -4.79 to 3.56 (2410-7650) -3.93 to 2.41 (0.007-0.052)






D Di is st tr ri ib bu ut ti io on n   o of f   I IG GF F- -1 1   S SD DS S   v va al lu ue es s* *
2 20 0% %
5 50 0% %
2 26 6. .3 3% % 1 13 3. .1 1% %
6 60 0. .6 6% %
6 61 1. .6 6% %































































































































3 30 0% %
H He ei ig gh ht t
g ga ai in n
a ac cc co or rd di in ng g
t to o   I IG GF F- -1 1
S SD DS S
v va al lu ue es s
0 0. .9 92 2
0 0. .6 67 7
0 0. .5 55 5
0 0. .7 74 4
0 0. .9 91 1
0 0. .3 32 2
0 0. .6 61 1
0 0. .1 11 1
0 0. .1 15 57 7
0 0. .3 33 3
0 0. .4 44 4
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and r=-0.105, and p=0.67 for the third year of treatment,
respectively). Although 15 children (30%) in the first year,
5 patients (13.1%) in the second year, and 5 patients
(19.2%) in the third year of therapy showed high IGF-1 
levels (>+2SDS), IGF-1/IGFBP-3 molar ratio of these 
children was not higher than the others. 
Discussion
GH therapy normalizes the subnormal IGF-1 levels in
GH deficient patients (7). However, IGF-1 levels may 
increase to supranormal values and this increase leads to
concerns about potential hazardous effect of IGF-1. IGF-1
is a mitogenic polypeptide that stimulates cell proliferation
and suppresses cellular apoptotic pathways to facilitate
cell growth (8). An increased level of IGF-1 receptor 
expression is present in some malignant tumors (9). 
Several case-control studies have demonstrated a strong
association between circulating IGF-1 concentrations and
the relative risk of specific cancers (10-12). Prostate, 
breast, colorectal, lung cancers are the most studied 
cancer types, and a link has been shown to exist between
IGF-1 levels and increased risk of carcinogenesis (11-16). 
IGFBP-3 is the most abundant binding protein of IGF-1
in the serum, and is an important component of the 
natural physiological regulation of IGF (9).  IGFBP-3 appears
to have a protective effect, inhibiting the mitogenic effect
of IGF-1 on cell proliferation by lowering the amount of the
free bioactive form of IGF-1. IGFBP-3 also facilitates 
apoptosis, possibly independent of its effect on IGF-1 (8).
Because a long-term sustained elevated serum IGF-1 
concentration may dispose to carcinoma, it is recommended
that measurements of IGF-1 and IGFBP-3 should be done
regularly in GH treated subjects (17). 
GH therapy increases both IGF-1 and IGFBP-3 levels
and helps to maintain a normal IGF-1/IGFBP-3 ratio, 
thereby having a compensatory effect  for high IGF-1 
levels (4). While monitoring GH therapy, not only IGF-1 
levels but also  IGFBP-3 levels may be important, and 
calculating IGF-1/IGFBP-3 molar ratio may give a crude es-
timate of  the free IGF-1 level. 
There was a significant increase in height SDS over the
first year of therapy in our patients, declining over the 
consecutive years. Delta height SDS was +0.62 at the end
of the first year, +0.31, in the second year, and +0.34 in
the third year. After onset of therapy, the molar ratio was
almost tripled, and stayed at a similar level (approximately
0.019) during the three-year follow-up. We could not find
any correlation between delta height SDS and mean IGF-1
SDS for each year. Patients with low and high IGF-1 levels
showed similar height increments during the 3 years of
treatment. This similar height gain can be explained in 
patients having a similar molar ratio at all stages, probably
reflecting a similar degree of free IGF-1 in all groups. This
equilibrium between IGF-1 and IGFBP-3 may have caused
the same level of bioavailibility of free IGF-1 at tissue level.
Unfortunately, we did not measure free IGF-1 levels in our
patients and therefore could not analyze free IGF-1 together
with molar ratio. It should also be noted that free IGF-1 
levels may not be similar even if molar ratios are the same
and that molar ratios may be a crude reflection of free IGF
(18). However, it may be concluded that higher dose of GH
treatment would not be necessary in patients with low
IGF-1 levels unless the molar ratio is also low.  
In conclusion, concomitant elevation of IGFBP-3 and
IGF-1 leads to a similar molar ratio in GH treated patients.
Evaluation of IGF-1 together with  IGFPB-3 and calculating
the molar ratio may be useful  for monitoring the GH effect
and for individualizing the therapy to enhance efficacy and
safety. 
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